Sana Biotechnology (NASDAQ:SANA) Sees Strong Trading Volume – What’s Next?

Posted by George Bondi on May 14th, 2026

Sana Biotechnology, Inc. (NASDAQ:SANA – Get Free Report) shares saw unusually-strong trading volume on Thursday . Approximately 20,133,916 shares traded hands during mid-day trading, an increase of 624% from the previous session’s volume of 2,780,300 shares.The stock last traded at $3.1850 and had previously closed at $3.20.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Wall Street Zen upgraded shares of Sana Biotechnology from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 9th. HC Wainwright dropped their price target on shares of Sana Biotechnology from $9.00 to $7.00 and set a “buy” rating on the stock in a research note on Wednesday, March 4th. Morgan Stanley reissued an “overweight” rating and set a $12.00 price target on shares of Sana Biotechnology in a report on Friday, March 13th. Zacks Research cut shares of Sana Biotechnology from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 3rd. Finally, Weiss Ratings downgraded shares of Sana Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 1st. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $9.50.

View Our Latest Research Report on Sana Biotechnology

Sana Biotechnology Stock Down 2.7%

The company has a market cap of $866.87 million, a price-to-earnings ratio of -3.34 and a beta of 2.17. The business has a fifty day simple moving average of $3.29 and a 200 day simple moving average of $3.98.

Sana Biotechnology (NASDAQ:SANA – Get Free Report) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01. Equities analysts anticipate that Sana Biotechnology, Inc. will post -0.59 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Mercer Global Advisors Inc. ADV acquired a new stake in shares of Sana Biotechnology during the 3rd quarter valued at approximately $36,000. TD Waterhouse Canada Inc. purchased a new stake in shares of Sana Biotechnology during the 3rd quarter worth approximately $37,000. Lyell Wealth Management LP acquired a new stake in shares of Sana Biotechnology in the 3rd quarter worth approximately $37,000. Rockefeller Capital Management L.P. increased its stake in Sana Biotechnology by 74.3% in the 4th quarter. Rockefeller Capital Management L.P. now owns 9,588 shares of the company’s stock valued at $39,000 after purchasing an additional 4,088 shares in the last quarter. Finally, Russell Investments Group Ltd. purchased a new position in Sana Biotechnology in the 3rd quarter valued at approximately $39,000. 88.23% of the stock is owned by hedge funds and other institutional investors.

Sana Biotechnology Company Profile

(Get Free Report)

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.